Clinical Nurse Specialists

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

2 days ago talkbio0Tagged Alzheimer 's psychosis, amisulpride, Clinical Nurse Specialists, Depression, Bipolar, IPO, LB-102, Nasdaq, Phase 3 Clinical Trials, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq

CNS Pharmaceuticals Pursues Public Offering to Fund Phase 2 GBM Trial After Cost Cuts

2 weeks ago talkbio0Tagged cash position, Clinical Nurse Specialists, Funding, Glioblastoma, IPO, layoffs, multiforme, public entity

CNS Pharmaceuticals; biotech; layoffs; IPO; public offering; phase 2 trial; glioblastoma multiforme; funding; cash position

TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases

6 months ago talkbio0Tagged cellular targeting, Clinical Nurse Specialists, degraders, Neurodegenerative Disorders, Plant seeds, Protein Degradation, Metabolic, TRIM21, TRIMTAC

targeted protein degradation, neurodegenerative diseases, TRIM21, TRIMTAC degraders, CNS therapeutics, seed funding, biotech startup

Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform

8 months ago talkbio0Tagged Alloys, AntiClastic Antisense Platform, Blood - brain barrier anatomy, Clinical Nurse Specialists, Drug Development, Genetic Medicine, RNA, sanofi

Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine